Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Sophia GeneticsSOPH -0.70%73 3-Year ROIIC % is 45.76 as of Dec. 2025. GuruFocus rates SOPH with a GF Score™ of 73/100 and a GF Value™ of $5.06 (Modestly Overvalued). The stock has 6 warning signs investors should review. Among 619 Healthcare Providers & Services companies, Sophia Genetics ranks better than 82.88% on this metric.
3-Year Return on Invested Incremental Capital (3-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 3-year.
Sophia Genetics's 3-Year ROIIC % for the quarter that ended in Dec. 2025 was 45.76%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
The industry rank for Sophia Genetics's 3-Year ROIIC % or its related term are showing as below:
SOPH's 3-Year ROIIC % is ranked better than 82.88% of 619
companies
in the Healthcare Providers & Services industry
Industry Median: 3.46
vs SOPH: 45.76
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
Sophia Genetics 3-Year ROIIC % Related Terms
Sophia Genetics 3-Year ROIIC % Historical Data
* Premium members only.
The historical data trend for Sophia Genetics's 3-Year ROIIC % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SOPH vs WEAV, NRC, MDRX: 3-Year ROIIC % Comparison
For the Health Information Services subindustry, Sophia Genetics's 3-Year ROIIC %, along with its competitors' market caps and 3-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sophia Genetics 3-Year ROIIC % vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Sophia Genetics's 3-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where Sophia Genetics's 3-Year ROIIC % falls into.
Sophia Genetics's 3-Year ROIIC % for the quarter that ended in Dec. 2025 is calculated as:
3-Year ROIIC %
=
3-Year Incremental Net Operating Profit After Taxes (NOPAT)**
/
3-Year Incremental Invested Capital**
=
( -70.906 (Dec. 2025) - -87.6824832 (Dec. 2022) )
/
( 100.637 (Dec. 2025) - 63.975 (Dec. 2022) )
=
16.7764832
/
36.662
=
45.76%***
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Annual data of NOPAT and Invested Capital was used to calculate 3-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
Sophia Genetics (SOPH) has a 3-Year ROIIC % of 45.76 as of Dec. 2025. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Sophia Genetics and its competitors. According to the industry distribution chart, Sophia Genetics ranks #106 out of 619 companies in the Healthcare Providers & Services industry, placing it in the top 17.1%.
Is Sophia Genetics' 3-Year ROIIC % too high?
Sophia Genetics' current 3-Year ROIIC % is 45.76. The Healthcare Providers & Services industry median 3-Year ROIIC % is 3.46. Sophia Genetics' value of 45.76 is 1222.5% above this industry median. Based on the distribution chart, Sophia Genetics ranks #106 out of 619 companies in the Healthcare Providers & Services industry, which is in the top quartile — a strong position relative to peers. Overall, Sophia Genetics has a GF Score™ of 73/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Sophia Genetics' 3-Year ROIIC % compare to WEAV and NRC?
According to the Healthcare Providers & Services industry distribution chart, Sophia Genetics ranks #106 out of 619 companies for 3-Year ROIIC %. This places Sophia Genetics in the top 17% of its industry — outperforming the majority of peers. The industry median 3-Year ROIIC % is 3.46. Sophia Genetics' value of 45.76 is 1222.5% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year ROIIC % for a Healthcare Providers & Services company?
The median 3-Year ROIIC % among Healthcare Providers & Services companies is 3.46, based on 619 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year ROIIC % significantly above this median, while those in the bottom quartile fall well below. However, 3-Year ROIIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sophia Genetics's current 3-Year ROIIC % of 45.76 is 1222.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year ROIIC % mean?
A high 3-Year ROIIC % can signal that a stock is expensive relative to its fundamentals. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Sophia Genetics and its competitors. For the Healthcare Providers & Services industry, the median 3-Year ROIIC % is 3.46 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sophia Genetics's current 3-Year ROIIC % is 45.76. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sophia Genetics stock overvalued right now?
Based on GuruFocus' analysis, Sophia Genetics (SOPH) is currently considered Modestly Overvalued. The stock's GF Value™ is $5.06, compared to a current price of $5.68 — trading 12.3% above its estimated fair value. The current 3-Year ROIIC % is 45.76 and 1222.5% above the Healthcare Providers & Services industry median of 3.46. Sophia Genetics' overall GF Score™ is 73/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year ROIIC % calculated?
3-Year ROIIC % is calculated from a company's financial statements. For Sophia Genetics (SOPH), the current 3-Year ROIIC % is 45.76 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sophia Genetics (SOPH) Overvalued in 2026?
Based on GuruFocus' analysis, Sophia Genetics stock appears to be overvalued.
The current stock price of $5.68 is trading 12.3% above its estimated GF Value™ of $5.06.
GuruFocus considers Sophia Genetics to be Modestly Overvalued.
Key valuation signals for SOPH:
3-Year ROIIC %: 45.76
GF Value™: $5.06 vs. price of $5.68 (12.3% above fair value)
Industry Position: 1222.5% above the Healthcare Providers & Services median (#106 of 619)
No single metric tells the full story. See the SOPH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sophia Genetics SA is a healthcare technology company dedicated to establishing the practice of data-driven medicine as the standard of care and for life sciences research. It has built a cloud-based SaaS platform capable of analyzing data and generating insights from complex multimodal data sets and different diagnostic modalities. The Company had a physical presence in three countries outside of its headquarters in Switzerland: France, the United States, and Brazil.
73GF Score
Get the complete analysis for SOPH
3-Year ROIIC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SOPH has been successfully added to your 
